Last updated on December 2018

Study of IW-1701 A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Type I or II Achalasia


Brief description of study

The objectives of this study are as follows:

In patients with primary Type I or II Achalasia, following a single 5-mg dose of IW-1701,

  • To assess the safety and tolerability
  • To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM)
  • To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast

Clinical Study Identifier: NCT02931565

Contact Investigators or Research Sites near you

Start Over

Cecile Guttermuth, PhD

Connecticut Clinical Research Foundation, Gastroenterology Institute
Bristol, CT United States

Deborah M Geno, CCRP

Mayo Clinic
Rochester, MN United States

Terri Radake, RN, CRCC

Washington University in St. Louis - School of Medicine
Saint Louis, MO United States

Tina C Higginbotham, MPA

Vanderbilt University Medical Center
Nashville, TN United States

Linda Taylor

University of Utah School of Medicine, Division of Gastroenterology, Hepatology & Nutrition
Salt Lake City, UT United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.